Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sentinel Will Start Small, FDA Tells IoM; Are Expectations Too Big?

This article was originally published in RPM Report

Executive Summary

Agency plans to launch two "mini-Sentinel" pilots, one using private data sources and one tying together Medicare, VA and DoD data. More importantly, agency is focusing on using Sentinel for signal strengthening-that is, to test signals generated via existing means, not generate new ones. That position seems to have broad support from thought leaders in epidemiology, but may not match stakeholder expectations for Sentinel

You may also be interested in...



Bristol-Myers Squibb/AstraZeneca Onglyza is Guinea Pig for FDA Mini-Sentinel Post-Market Surveillance

FDA’s Congressionally-mandated active surveillance system, Sentinel, is ready for shakedown cruises in 2011. One of the first projects will be a close examination of real-world experience and cardiovascular events associated with saxagliptin. That’s a dubious distinction for BMS/AZ, the co-marketers of Onglyza–but it also sets up a new dynamic that all sponsors should watch.

Smart, Safe, Saxy Choice: Why FDA Selected Onglyza for Mini-Sentinel Project

FDA has a lot at stake in the first tangible drug surveillance project through Mini-Sentinel and a lot of audiences to please: Congress, regulated industry, academia, the drug safety community, media and general public. Here is how FDA explained the choice of saxagliptin as the first focus of the project.

Bristol-Myers Squibb/AstraZeneca Onglyza is Guinea Pig for FDA Mini-Sentinel Post-Market Surveillance

FDA’s Congressionally-mandated active surveillance system, Sentinel, is ready for shakedown cruises in 2011. One of the first projects will be a close examination of real-world experience and cardiovascular events associated with saxagliptin. That’s a dubious distinction for BMS/AZ, the co-marketers of Onglyza–but it also sets up a new dynamic that all sponsors should watch.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel